Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Nephrology

Inside the Kidney: Scarring and Structural Changes

At a Glance

Arterionephrosclerosis develops when long-term high blood pressure narrows kidney vessels, reducing blood flow and causing scarring in filters and surrounding tissue. IFTA on biopsy estimates chronic damage, while heavy proteinuria or blood in urine may suggest another disease.

Arterionephrosclerosis is the result of a physical “chain reaction” caused by chronic high blood pressure. To understand how it damages your kidneys, it helps to look at the three main structures affected: the blood vessels, the filters, and the surrounding tissue [1][2].

  1. Vessel Damage: High pressure stresses the walls of the arterioles (the tiny blood vessels feeding the kidney). Over time, these walls thicken in a process involving arteriolar hyalinosis (a glassy protein buildup) and vessel thickening [1][3]. While high blood pressure causes this, it is not the only cause; diabetes and normal aging can also thicken these vessels.
  2. Starvation (Ischemia): Because the blood vessels are narrowed, less blood can reach the kidney’s filters, known as glomeruli. This lack of blood flow is called ischemia [1][4].
  3. Scarring (Glomerulosclerosis): Starved of oxygen and nutrients, the filters begin to shrivel and scar. When a filter is completely scarred and no longer works, it is called global glomerulosclerosis [4][5].

The Importance of IFTA

While the damage to the filters is critical, doctors also look closely at the “background” tissue of the kidney. This is where Interstitial Fibrosis and Tubular Atrophy (IFTA) occurs [2][6].

  • Interstitial Fibrosis: This is the formation of scar tissue in the spaces between the kidney’s filters and tubes [7].
  • Tubular Atrophy: This happens when the tiny tubes that process urine begin to shrink and waste away [7].

IFTA is a nonspecific marker of chronic damage, but it is one of the most important predictors of how your kidney disease will progress [8]. A higher percentage of IFTA on a biopsy report usually suggests a higher risk of progressing toward advanced kidney disease, though grading scales (mild, moderate, severe) can vary depending on the pathology laboratory [8][9].

Reading a Pathology Report

If you and your doctor decide the benefits of a kidney biopsy outweigh the risks, the report will contain technical terms. Here is a guide to the most common ones:

Term What it Means in Plain Language
Arteriolar Hyalinosis A buildup of glassy, scar-like material in the walls of the tiny blood vessels [1].
Global Glomerulosclerosis An entire kidney filter has turned into a ball of scar tissue and is non-functional [4].
Ischemic Changes Damage caused by a lack of oxygen and blood flow [1].
IFTA Grade/Percentage The amount of general scarring in the background kidney tissue. Often graded as mild, moderate, or severe [10].

Note: A biopsy involves taking a very small sample of tissue. Because the sample is tiny, it may not perfectly represent the entire kidney.

Ruling Out Other Causes

Doctors must be careful not to assume that every patient with high blood pressure and kidney damage has arterionephrosclerosis. If your lab work shows certain clues, your doctor may investigate other diseases:

  • Glomerulonephritis: If you have hematuria (blood in the urine) or an “active sediment” (cells or casts seen under a microscope), it suggests the filters might be inflamed by an immune response, rather than just scarred by pressure [11][12].
  • Diabetic Kidney Disease: For those with diabetes, doctors look for specific biopsy patterns or heavy protein leakage to distinguish it from blood pressure damage [1][13].
  • APOL1-Associated Disease: Genetic variants in the APOL1 gene can increase susceptibility to progressive kidney scarring. These variants are more frequent in people with recent African ancestry [14]. Ancestry itself is not a diagnosis, and testing for APOL1 is highly individualized; it may involve genetic counseling to help you understand what the results mean for you and your family [15].
  • Nephrotic-Range Proteinuria: If you are losing a massive amount of total protein in your urine (often >3.5 grams per day), it is a major warning sign. It often points toward other conditions, such as FSGS (Focal Segmental Glomerulosclerosis) or severe diabetic kidney disease, rather than simple chronic hypertension [16][17].

Distinguishing between these conditions is vital because while arterionephrosclerosis is managed primarily through blood pressure and cardiovascular risk control, some other conditions may require targeted immune-suppressing therapies [11][14].

Common questions in this guide

What is arterionephrosclerosis, and how does high blood pressure cause it?
Arterionephrosclerosis is chronic kidney damage linked to long-standing high blood pressure. High pressure thickens and narrows the kidney’s small blood vessels, reducing blood flow and causing injury and scarring in the kidney filters and surrounding tissue.
What are ischemic changes on a kidney biopsy?
Ischemic changes are injuries caused by reduced blood flow and oxygen. In arterionephrosclerosis, narrowed small vessels can limit blood supply to the kidney filters and contribute to scarring.
What does IFTA mean on a kidney biopsy report?
IFTA stands for interstitial fibrosis and tubular atrophy. It describes scar tissue between the kidney’s filters and tubes and shrinkage of the urine-processing tubes; a higher percentage usually means more chronic damage and a greater risk of progression, although grading can vary by laboratory.
What does global glomerulosclerosis mean?
Global glomerulosclerosis means that an entire kidney filter, called a glomerulus, has become scarred and no longer works. The number of affected filters helps show how much chronic damage is present, but a biopsy samples only a small part of the kidney.
Can blood or a lot of protein in my urine mean something other than high blood pressure damage?
Yes. Blood in the urine, cells or casts seen under a microscope, or nephrotic-range protein loss—often more than 3.5 grams per day—can suggest glomerulonephritis, FSGS, or severe diabetic kidney disease instead of simple arterionephrosclerosis. Your clinician can combine urine tests, other laboratory results, and sometimes a biopsy to investigate.
Could APOL1 testing help explain progressive kidney scarring?
Some APOL1 gene variants increase susceptibility to progressive kidney scarring, and they are more common in people with recent African ancestry. Testing is individualized because ancestry alone is not a diagnosis, and genetic counseling can help explain what a result may mean for you and your family.
How is arterionephrosclerosis usually managed?
Management focuses mainly on controlling blood pressure and reducing cardiovascular risk. If urine or biopsy findings suggest another kidney disease, treatment may differ and could include targeted immune-suppressing therapy for selected conditions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report show more 'ischemic' damage or more 'segmental' scarring, and what does that mean for my prognosis?
  2. 2.What percentage of 'IFTA' was found in my sample, and does that change how aggressively we should manage my condition?
  3. 3.Are there any findings, like active urine sediment or immune deposits, that suggest my kidney damage might be from something other than high blood pressure?
  4. 4.Could my clinical presentation warrant testing for genetic risk factors, like APOL1 variants, or meeting with a genetic counselor?
  5. 5.Is the amount of protein in my urine (proteinuria) typical for arterionephrosclerosis, or is it high enough that we should reconsider other diagnoses like glomerulonephritis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Hypertensive Nephrosclerosis: Pathological Changes and Overlap with Diabetic Nephropathy.

    Qasim H, Ktaifan M, Awawdeh A, et al.

    Cureus 2025; (17(9)):e92949 doi:10.7759/cureus.92949.

    PMID: 41141162
  2. 2

    Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.

    Costantino VV, Gil Lorenzo AF, Bocanegra V, Vallés PG

    Cells 2021; (10(11)) doi:10.3390/cells10113146.

    PMID: 34831368
  3. 3

    The Key Role of Epithelial to Mesenchymal Transition (EMT) in Hypertensive Kidney Disease.

    Seccia TM, Caroccia B, Piazza M, Rossi GP

    International journal of molecular sciences 2019; (20(14)) doi:10.3390/ijms20143567.

    PMID: 31330886
  4. 4

    APOL1 Risk Alleles are Associated with More Severe Arteriosclerosis in Renal Resistance Vessels with Aging and Hypertension.

    Hughson MD, Hoy WE, Mott SA, et al.

    Kidney international reports 2016; (1(1)):10-23 doi:10.1016/j.ekir.2016.03.002.

    PMID: 27610422
  5. 5

    Hypertension and age-related focal global glomerulosclerosis are associated with biomarkers for cellular senescence.

    Hughson MD, Ali AA, Okabayashi Y, et al.

    Physiological reports 2026; (14(3)):e70730 doi:10.14814/phy2.70730.

    PMID: 41612662
  6. 6

    Autopsy study examining non-chronic kidney disease versus chronic kidney disease caused by hypertensive-nephrosclerosis in elderly subjects.

    Yamaguchi Y, Takei T, Matsuda Y, et al.

    Clinical and experimental nephrology 2022; (26(6)):530-539 doi:10.1007/s10157-022-02189-x.

    PMID: 35118548
  7. 7

    Renal Fibrosis in Lupus Nephritis.

    Sciascia S, Cozzi M, Barinotti A, et al.

    International journal of molecular sciences 2022; (23(22)) doi:10.3390/ijms232214317.

    PMID: 36430794
  8. 8

    Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study.

    Yamanouchi M, Hoshino J, Ubara Y, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(7)):1182-1188 doi:10.1093/ndt/gfy121.

    PMID: 29788462
  9. 9

    Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-β-d-Glucosaminidase, and Urinary β2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy.

    Mise K, Hoshino J, Ueno T, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2016; (11(4)):593-601 doi:10.2215/CJN.04980515.

    PMID: 26801478
  10. 10

    Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis.

    Wilson PC, Kashgarian M, Moeckel G

    Clinical kidney journal 2018; (11(2)):207-218 doi:10.1093/ckj/sfx093.

    PMID: 29644061
  11. 11

    Clinical Phenotypes and Long-term Prognosis in White Patients With Biopsy-Verified Hypertensive Nephrosclerosis.

    Øvrehus MA, Oldereid TS, Dadfar A, et al.

    Kidney international reports 2020; (5(3)):339-347 doi:10.1016/j.ekir.2019.12.010.

    PMID: 32154455
  12. 12

    Interest of a Kidney Biopsy to Rule out ANCA-Associated Renal Vasculitis in Glomerulonephritis Patients with a Positive ANCA.

    Garo F, Aglae C, Perrochia H, et al.

    Case reports in nephrology and dialysis 2022; (12(1)):73-80 doi:10.1159/000521862.

    PMID: 35702377
  13. 13

    Clinico-pathological features of kidney disease in diabetic cases.

    Furuichi K, Shimizu M, Okada H, et al.

    Clinical and experimental nephrology 2018; (22(5)):1046-1051 doi:10.1007/s10157-018-1556-4.

    PMID: 29564666
  14. 14

    Hypertension-attributed nephropathy: what's in a name?

    Freedman BI, Cohen AH

    Nature reviews. Nephrology 2016; (12(1)):27-36 doi:10.1038/nrneph.2015.172.

    PMID: 26553514
  15. 15

    One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.

    Kopp JB, Rosenberg AZ

    Advances in anatomic pathology 2019; (26(3)):215-219 doi:10.1097/PAP.0000000000000221.

    PMID: 30624253
  16. 16

    Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland.

    Perkowska-Ptasinska A, Deborska-Materkowska D, Bartczak A, et al.

    BMC nephrology 2016; (17(1)):194 doi:10.1186/s12882-016-0410-8.

    PMID: 27884116
  17. 17

    Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis.

    Sumida K, Hoshino J, Ueno T, et al.

    PloS one 2016; (11(1)):e0147690 doi:10.1371/journal.pone.0147690.

    PMID: 26809068

This page is for informational purposes only and does not constitute medical advice. A nephrologist or pathologist should interpret your biopsy, urine findings, and genetic testing in the context of your care.

Get notified when new evidence is published on arterionephrosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.